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Introduction: Platelet adhesion to collagen under high shear rates depends on the optimal size of the von
Willebrand factor (VWF) multimers, which is determined by their limited proteolysis. The present study at-
tempts to identify the role of hemostatic-ﬁbrinolytic enzymes (thrombin, plasmin) and leukocyte-derived
proteases (matrix metalloproteinase (MMP)-8, MMP-9, neutrophil elastase) in the cleavage of VWF and to
characterize the effect of ﬂow and platelets on this proteolysis and its functional consequences on platelet ad-
hesion.
Methods and results
According to VWF immunoblots, plasmin, neutrophil elastase and thrombin at concentrations of in vivo rel-
evance resulted in extensive degradation of VWF within several minutes. Platelets protected VWF against
this proteolysis under static conditions, whereas perfusion of the proteases at 3350 s-1 shear rate over
VWF immobilized on artery cross sections enhanced its degradation and blocked the protective effect of
platelets. In parallel with VWF digestion, the examined proteases impaired the VWF-dependent platelet ad-
hesion as reﬂected in the decreased surface-bound GpIIb/IIIa immunoreactivity following perfusion of
collagen-coated surfaces or artery sections with blood and plasmin, neutrophil elastase or thrombin. Within
the time frame of minutes no VWF cleavage could be detected under static or ﬂow conditions after exposure
to MMP-8 and MMP-9 at concentrations relevant to physiological neutrophil counts.
Conclusion: Our results indicate a shear- and platelet-dependent role for several proteases in the local mod-
ulation of the VWF function.© 2011 Elsevier Ltd. Open access under CC BY license.Introduction
Von Willebrand factor (VWF) is a glycoprotein that can be found
in blood plasma, in the α-granules of platelets and in the subendothe-
lial matrix of blood vessels following release from endothelial cells.
The main functions of this glycoprotein are essential for normal he-
mostasis: it promotes platelet adhesion to thrombogenic surfaces
through the platelet receptor GpIb under high shear rate conditions
and carries factor VIII in plasma prolonging its lifetime in circulation.
VWF binds to collagen types I, III, VI and to platelet surface glycopro-
teins GpIb and GpIIb/IIIa (reviewed in [1]). Binding of VWF to ﬁbrin
inﬂuences platelet adhesion at the site of vascular injury [2]. The
binding of soluble VWF to nonactivated platelets is tightly regulated
to prevent aggregation in the circulation, but VWF immobilized
onto a surface is highly reactive toward ﬂowing platelets. Exposure
to shear rates in the range of 500 and 5000 s-1, which is typical for
the small arterioles [3] or stenotic coronary arteries [4], appears to, Department of Medical Bio-
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license.be an essential factor in the control of VWF reactivity. While circulat-
ing VWF multimers are in coiled conformation that shields the A1 do-
main from interacting with platelets, binding to a substrate under
shear stress extends the shape of the molecule with consequent in-
crease in platelet adhesiveness [5]. Another regulatory tool in the
VWF – platelet interactions is the modiﬁcation of the size of VWF
multimers through proteolysis, which decreases the reactivity of
VWF. The smallest form of VWF is a dimer of identical disulﬁde-
linked subunits [6]. In the largest multimers the number of subunits
can be as many as 50 to 100 while the molecular mass ranges from
540 kDa for the dimer to several thousand kDa for the largest multi-
mers. Proteolytic cleavage by a metalloproteinase (ADAMTS-13) is re-
sponsible for reducing the size of large VWF multimers in the plasma
by cleaving the subunit at the bond between Tyr842 and Met843 [7].
Proteolysis restricts the positive effects of ﬂow on VWF reactivity, be-
cause under shear stress VWF changes its three-dimensional struc-
ture [5] which enables the cleavage by ADAMTS-13. Deﬁciency in
the ADAMTS-13 function results in thrombotic thrombocytopenic
purpura (TTP) [8,9] but the ADAMTS-13 levels do not always corre-
late with the severity of TTP [8,10]. Accordingly additional regulatory
mechanisms should be considered. In vivo adhered platelets recruit
leukocytes from circulating blood, predominantly neutrophils,
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vated and secrete elastase, cathepsin G and matrix metalloprotei-
nases. The cleavage of VWF by neutrophil granulocyte-derived
proteases has been documented [12–15] and the cleavage sites in
VWF have been recently identiﬁed [16], but no investigations have
been carried out under ﬂow conditions or in the presence of platelets
and thrombogenic surfaces. The importance of leukocyte-derived ser-
ine proteases in the cleavage of oxidized VWF has been recently
pointed out as a potential compensatory mechanism for the partial
inactivation of ADAMTS-13 by reactive oxygen species originating
from the same cells [17].
In thrombi VWF is exposed to additional proteases. Thrombin is
generated in the blood coagulation cascade, while plasmin, as a
main ﬁbrinolytic enzyme is produced by plasminogen activators
from plasminogen. The concentration of these enzymes is in the
range above 10 nM in thrombi and this environment also provides a
partial protection from plasma inhibitors [18]. About 10 nM thrombin
is present in whole blood at the point of clotting [19] and 20 nM neu-
trophil elastase concentration is expected in cell suspension of degra-
nulated PMNs [20,21]. Data on VWF degradation by plasmin and
thrombin are limited [22–24] and the impact of ﬂow and platelets
on the proteolytic susceptibility of VWF to these proteases has not
been characterized in conjunction with its functional consequences
on platelet adhesion to the arterial wall. The present study addresses
these aspects of the VWF proteolysis.Materials and Methods
Puriﬁed enzymes
Active enzyme concentration of human neutrophil elastase (Serva
Electrophoresis Gmbh, Heidelberg, Germany) was determined as de-
scribed previously [18]. Recombinant human MMP-8 and MMP-9
proenzymes (R&D Systems, Abingdon, England) were activated with
1 mM p-aminophenylmercuric acetate (APMA, Sigma-Aldrich Kft.,
Budapest, Hungary) at 37 °C for 1 h and 24 h, respectively, and their
activity was determined by gelatin substrate zymography [25].
Bovine thrombin was purchased from Serva Electrophoresis Gmbh,
Heidelberg, Germany, thrombin was further puriﬁed by ion-
exchange chromatography on sulfopropyl-Sephadex yielding a prep-
aration with speciﬁc activity of 2100 IU/mg [26] and 1 IU/ml was con-
sidered equivalent to approximately 10.7 nM by active site titration
[27]. MMP2/MMP-9 Inhibitor I [(2R)-2-[(4-biphenylylsulfonyl)
amino]-3-phenylpropionic acid] for the inhibition of MMP-9 and
MMP-Inhibitor I (4-Abz-Gly-Pro-D-Leu-D-Ala-NHOH) for the inhibi-
tion of MMP-8 (Calbiochem, LaJolla, CA) were applied at 5 μM con-
centration each. Pefabloc (aminoethyl-benzenesulfonylﬂuoride,
Serva Electrophoresis Gmbh, Heidelberg, Germany) was used for the
inhibition of serine proteases at a concentration of 10 mM.Preparation of human artery cryosections and collagen-coated surfaces
The study protocol was approved by the institutional and regional
ethical board. Human iliac artery was removed from deceased healthy
organ donors, immediately frozen in 2-methylbutane in dry ice and
stored at −70 °C. Cryosections (6 μm thickness) of the artery were
placed on poly-L-lysine-coated slides (“Poly-Prep Slides”, Sigma-
Aldrich Kft., Budapest, Hungary) 1–3 days before the experiments
and stored at−20 °C until use. Collagen (Helena Biosciences Europe)
was diluted to 100 μg/ml at 4 °C in 1.5 mM KH2PO4, 8.1 mM Na2HPO4
buffer pH 7.4 containing 137 mM NaCl and 2.7 mM KCl (PBS),
incubated for 15 minutes at 37 °C and 50 μl was applied to poly-L-
lysine-coated slides. Polymerisation of collagen took place at 37 °C
for 24 hours.Proteolysis of VWF under static conditions
In the absence of platelets puriﬁed multimeric human VWF (Hae-
mate P500, Helena Biosciences Europe) at 10 μg/ml in 10 mM Hepes
150 mM NaCL pH 7.4 was incubated with the studied enzymes at
various concentrations and samples were taken at different times
for immunoblotting. In order to prevent the activation of platelets
by the proteases, lyophilized platelets (Helena Biosciences Europe)
were used when the effect of platelets was evaluated under static
conditions and accordingly this assay reﬂects only properties of plate-
lets independent of activation. In terms of VWF interactions these
lyophilized platelets retain their basic hemostatic properties as evi-
denced by their widely accepted application in clinical laboratories
(reviewed in [28]). These experiments were performed in the cuvette
of a Carat TX4 four-channel optical aggregometer (Carat Diagnostics,
Budapest, Hungary), where gentle stirring maintained the homoge-
neity of the platelet suspension, but did not change the compact
(“static”) conformation of VWF. In order to remove any traces of plas-
ma protease inhibitors lyophilized platelets were washed in 50 mM
Tris–HCl 150 mM NaCl pH 7.4 four times and centrifuged for 10 min
at 80,000 g. Thereafter platelets were suspended in 10 μg/ml VWF so-
lution at 200,000 /μl count and the examined proteases were added at
various concentrations. Platelet agglutination was initiated with
1.5 mg/ml ristocetin (Helena Biosciences Europe) and monitored in
the aggregometer. In parallel samples were taken for VWF immuno-
blotting. In some experiments before the aggregometric assay
washed lyophilized platelets were preincubated with 50 nM plasmin
for 15 minutes followed by inhibition of plasmin with Pefabloc at
10 mM in order to differentiate the functional consequences of cell
surface receptor and VWF degradation by the enzyme. In order to
check the non-speciﬁc absorption of enzymes to platelets, after the
wash procedure platelets were resuspended in plasmin solution and
following centrifugation as described above plasmin activity
(expressed in ΔA405/min) in the supernatant was measured on
0.2 mM Spectrozyme-PL (H-D-norleucyl-hexahydrotyrosyl-lysine-p-
nitroanilide, American Diagnostica, Pfungstadt, Germany).
Proteolysis of VWF under ﬂow conditions
Artery cross sections on poly-L-Lys-coated or collagen-coated
slides were perfused as previously described [29] in a parallel-plate
chamber with VWF and lyophilized platelets or with VWF alone.
The perfusion chamber was constructed on the slides using a 0.3 cm
wide and 1.5 cm long ﬂow channel cut into a piece of double-sided
tape (Scotch, 1.27 cm wide, 64 μm thick), which was sandwiched to
a methacrylate cover (2.3 cm x 3.8 cm) containing the inlet and outlet
tubing (1-mm internal diameter Tygon). Assuming laminar ﬂow con-
ditions, the shear rate at the surface of the section was 3350 s-1,
according to the formula 1.03*6 Q/(w*h2), where Q is the ﬂow rate
in ml/s, w and h are the width and the height of the ﬂow path in
cm, respectively [30]. The initial VWF perfusion was followed by a
1.5-min wash with PBS and a 1.5-min perfusion with the examined
enzyme solution. The out-ﬂowing solution was collected and the in-
hibitor of the respective enzyme was added immediately. This
solution was concentrated with polyethylene glycol 20.000 (Sigma-
Aldrich Kft., Budapest, Hungary) and was used for Western Blot
analysis of VWF fragments.
Western Blot Analysis of VWF and its proteolytic fragments
Load buffer containing 100 mM Tris–HCl 100 mM NaCl, 5%(w/v)
SDS, 5%(v/v) β-mercapto-ethanol, pH 8.2 was added to the samples
collected in the proteolytic reactions at a ratio of 1:4 followed by
heat-treatment at 95 °C for 3 min. After gel electrophoresis, samples
were electroblotted onto nitrocellulose membranes, and VWF along
with its degradation products were detected by polyclonal rabbit
Fig. 1. Degradation of VWF by plasmin and neutrophil elastase under static condi-
tions. Puriﬁed human VWF (10 μg/ml) was incubated for 30 min with plasmin (A) or
neutrophil elastase (C) at the indicated concentrations or for various times with 100
nM plasmin (B) or 50 nM neutrophil elastase (D) at 37 °C. Proteolytic cleavage prod-
ucts were detected by Western Blot analysis as described in Materials and Methods.
Fig. 2. VWF proteolysis under static conditions in the presence of platelets. Ristoce-
tin (1.5 mg/ml) was used to initiate agglutination of 200,000 /μl platelets in 10 μg/ml
VWF solution and the transparency of the suspension was monitored in an aggreg-
ometer. Plasmin was added to the platelet suspension before ristocetin where indicat-
ed. Representative aggregation curves of 5 measurements are shown. The inset shows a
parallel immunoblot of the same sample for the detection of VWF cleavage products.
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Hungary) followed by goat-anti-rabbit IgG peroxidase conjugate.
The captured secondary antibodies were visualized using the ECL
Western blotting analysis system (GE Healthcare, Uppsala, Sweden).
Visualization of adherent platelets
Indirect immunoﬂuorescence microscopy was used to detect
platelets adhered to the tissue samples. The sections were blocked
with 200 μl 50 mM Tris–HCl, 100 mM NaCl, 0.02%(w/v) NaN3 pH 7.4
(TBS) containing 20 g/l bovine serum albumin (BSA) for 30 min fol-
lowed by washing with TBS. Afterwards they were incubated for
60 min with 100 μl 4 μg/ml mouse monoclonal antibody against
human CD41 GpIIb/IIIa (Biodesign International, Saco, USA) diluted
in TBS-BSA. The slides were washed three times with TBS and 100 μl
2 μg/ml Alexa Fluor 488 goat-anti-mouse IgG (Invitrogen, Budapest,
Hungary) diluted in TBS-BSA was added and incubated for 30 min.
The slides were washed 3 times and glass coverslips were afﬁxed
over a drop of 50%(v/v) glycerol in TBS. Confocal ﬂuorescent images
were taken from the slides using a Zeiss LSM510 confocal laser scan-
ning microscope equipped with a 20× 1.4 objective (Carl Zeiss, Jena,
Germany). The green ﬂuorescent signal was acquired using a 488-
nm excitation laser line (10% intensity) and emission was detected
in the 500–530 nm wavelength range. All steps were carried out at
22 °C, at which temperature no proteolytic degradation of platelet re-
ceptors by plasmin can be detected [31].
Data analysis of platelet adhesion to the vessel wall
The quantiﬁcation of platelets adhered to the vessel wall was per-
formed with the Scion Image software (Scion Corp, Frederick, Mary-
land) selecting the region of interest, calculating its surface area in
pixels and setting a threshold intensity value for automatic identiﬁca-
tion of the area covered by adhered platelets. The area covered by
platelets is reported in percentage of the whole area as mean
±S.E.M. from n=5 images. For estimating the statistical signiﬁcance
of differences Student's two-sample t-test was used.
Results
Proteolysis under static conditions in the absence of platelets
The degradation of VWF was evaluated at protease concentrations
with physiological relevance. Plasmin at 5 nM, a concentration that is
sufﬁcient to completely dissolve ﬁbrin (its primary intravascular sub-
strate) within 30 min [32] generated VWF degradation products at
the lowest limit of detectability within the same time interval
(Fig. 1A). At concentrations relevant to thrombolytic therapy (over
100 nM) [33] plasmin digested the intact VWF monomers almost
completely at 30 min and initial degradation products could be
detected as early as after 1.5 min incubation (Fig. 1B). Although neu-
trophil elastase generated different proteolytic products (Fig. 1C), its
efﬁciency in degrading VWF appears to be similar to that of plasmin
based on the time course of digestion with comparable enzyme con-
centrations (Fig. 1D). In contrast to plasmin and elastase, MMP-9
and MMP-8 at 20 nM, a concentration expected in suspensions of
neutrophil leukocytes with physiological cell count [34] degraded
VWF very slowly and cleavage products could be detected only after
24-h digestion. The efﬁciency of thrombin in VWF degradation was
similarly low. No cleavage products could be detected after 30 min di-
gestion even at 100 nM thrombin, a concentration 10-fold higher
than the values observed in blood at the point of clotting [19] (not
shown). The presence of 1 mM CaCl2 did not affect the time course
and the enzyme concentration dependence of VWF degradation by
plasmin and elastase evaluated as described for Fig. 1 (data notshown) and accordingly calcium effects were not investigated further
in different experimental setups.
Proteolysis under static conditions in the presence of platelets
The effects of platelets on the proteolysis of VWF were evaluated
in two assay systems: ristocetin-induced platelet agglutination to
monitor the changes of VWF function and immunoblot to detect in-
tact and fragmented VWF monomers (Fig. 2). Plasmin decreased the
maximal aggregation of platelets and later the aggregates disas-
sembled (Fig. 2), but this effect was not observed if platelets were
pre-treated with plasmin and the enzyme was inhibited prior the ag-
glutination assay suggesting that this loss of function is based on VWF
and not surface receptor degradation. Such a conclusion is supported
by the parallel immunoblots of the same samples, which indicated
VWF cleavage products (Fig. 2, Inset), but the time course of their ap-
pearance was signiﬁcantly slower compared to the proteolytic rate in
the absence of platelets (Fig. 2, Inset vs. Fig. 1B). The rest of the
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did not produce any cleavage products in the presence of platelets
and did not lower the maximal aggregation when applied at concen-
trations with detectable proteolytic effect in the absence of platelets
(data not shown). Ristocetin in the absence of platelets did not affect
VWF digestion with any of the examined proteases (data not shown).
Thus, we can conclude that platelets protect VWF against proteolysis
by various proteases probably through decreased lytic susceptibility
of the cell-bound VWF. Non-speciﬁc absorption of enzymes to plate-
let surfaces cannot account for this effect, because according to our
amidolytic activity assay, following sedimentation of lyophilized
platelets suspended in plasmin solution supernatants retain approxi-
mately 80% of the original enzymatic activity.
Proteolysis under ﬂow conditions
Proteolysis of VWF was evaluated in a ﬂow chamber, where VWF
was immobilized to an artery cross-section followed by protease per-
fusion at 3350 s-1 shear rate on the surface (Fig. 3). Shear forces ap-
pear to sensitize VWF to the action of proteases. The 1.5-minFig. 3. Cleavage of VWF by plasmin, neutrophil elastase and thrombin under ﬂow
conditions.VWF (10 μg/ml) alone or in a mixture with 200,000/μl lyophilized platelets
was perfused at 3350 s-1 shear rate over collagen surface as described in Materials and
Methods. Thereafter plasmin (A), neutrophil elastase (B) or thrombin (C) at the indi-
cated concentrations was perfused over the surface at the same ﬂow rate. VWF cleav-
age products in the outﬂowing solution were detected by Western Blot analysis.perfusion resulted in a more extensive degradation by plasmin com-
pared to the static digestion with identical enzyme concentrations
(Fig. 3A vs. Fig. 1). Proteolysis by neutrophil elastase and thrombin
was affected to a lesser degree by shear, whereas MMP-8 and MMP-
9 at the abovementioned physiologically relevant concentration (20
nM) did not cleave VWF even under the applied ﬂow conditions
(data not shown). In contrast to the static system, in the perfusion
chamber platelets did not protect VWF against proteolysis by neutro-
phil elastase and thrombin (Fig. 3B and C), but importantly, enhanced
the degradation by plasmin as indicated by the increase in the frac-
tion of fragments with size smaller than 140 kDa in Fig. 3A.Modulation of VWF function by proteolysis under ﬂow conditions
VWF-dependent platelet adhesion was evaluated on artiﬁcial col-
lagen surfaces or artery cryosections. Following initial perfusion with
blood, platelets adhered to the surface and could not be detached by
perfusion of enzyme-free buffer at 3350 s-1 shear rate (Fig. 4A).
Plasmin, neutrophil elastase and thrombin perfusion signiﬁcantly
decreased platelet adhesion while matrix metalloproteinases had no
effect (Fig. 4B).Fig. 4. Platelet coverage of thrombogenic surfaces. Collagen surface (1.) or arterial
cryosection (2.) was perfused with citrated whole blood for 1.5 min at 3350 s-1 shear
rate in the ﬂow chamber described in Materials and Methods followed by a perfusion
of PBS (control) or 10 nM plasmin. Platelets were visualized by indirect immunoﬂuo-
rescence (A) and images were analyzed for platelet coverage before (control) and
after the perfusion with plasmin (10 nM), neutrophil elastase (10 nM), thrombin
(100 nM), MMP-8 (20 nM), MMP-9 (20 nM). In panel B the area of collagen surfaces
covered by platelets is shown as percentage of the total area (mean±SEM, n=5,
* pb0.01).
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The data presented in this report show that proteases with well-
known function in the resolution of blood clots (plasmin, neutrophil
elastase) extensively degrade VWF (Fig. 1) at concentrations with ef-
ﬁcient ﬁbrinolytic activity [32] and thus extend the concept of tran-
sient compartments in hemostatic or pathological thrombi [35] with
a new mechanism. The disassembly of the clots may be attributed
not only to the dissolution of the ﬁbrin network, but also to the
break-down of the adhesive molecular links between platelets and
blood vessel wall formed by VWF multimers. This suggested role is
supported by our results from a ﬂowmodel of platelet adhesion to ar-
tery cross sections and collagen, in which the VWF dependence of
adhesion has been previously characterized [36]. Here the same pro-
teases detach platelets adhered to collagen or artery wall sections at
concentrations that efﬁciently degrade VWF (Fig. 4). Importantly,
not all neutrophil proteases appear to be involved in this mechanism.
Here we could not detect cleavage of VWF by MMP-8 and MMP-9 at
20 nM, a concentration that we have recently shown to be efﬁcient
in the proteolytic modiﬁcation of the arterial wall structure [34].
This result is in agreement with a recent report [16] demonstrating
no VWF degradation by MMP-9 under static conditions and partial di-
gestion only under shear and at higher enzyme concentrations (50
nM or more). Thus, MMP-8 and MMP-9 appear to favour platelet ad-
hesion rendering the arterial wall more thrombogenic [34] and spar-
ing VWF (present results) in contrast to elastase, which increases the
adhesiveness of the vessel wall [34], but at a later stage promotes
platelet detachment (Fig. 4) through VWF degradation (Figs. 1C&D
and 3).
At sites of vascular injury ultra-large VWF multimers (of more
than 40 monomeric subunits) are released from their storage
granules in endothelial cells [37] and platelets [38]. Their hyperactiv-
ity [39] is essential for shear-induced platelet aggregation and rapid
formation of hemostatic plugs. However, the propagation of such hy-
peractive VWF derivatives in the systemic circulation would cause a
prothrombotic state as observed in TTP. This detrimental situation is
normally prevented via VWF cleavage by ADAMTS-13 on the surface
of endothelial cells [40] or platelets [41]. Here we demonstrate sever-
al alternative possibilities for negative feed-back control of VWF
function at sites of platelet adhesion and activation. Platelets support
procoagulant reactions (reviewed in [42]), the ﬁnal outcome of which
is ﬁbrinogen-ﬁbrin conversion catalyzed by thrombin. At the point of
blood clotting the concentration of thrombin is 10 nM [19] and at this
concentration thrombin further supports platelet adhesion through
modiﬁcations of the arterial wall structure [34], but it does not cleave
VWF (present results) and thus the adhesive properties of VWF re-
main unaltered. At later stages of whole blood clotting, the thrombin
concentration rises to values of several hundred nM [19]. Such con-
centrations of thrombin are sufﬁcient to cleave VWF under ﬂow
(Fig. 3) and thus excessive and sustained generation of thrombin
would restrict the availability of hyperactive VWF to the locus of its
release. At later stages of thrombus development, when the classic
(plasminogen-dependent) and alternative (leukocyte-dependent)
[43] ﬁbrinolytic pathways are activated, additional proteases with
the potential to modify the size of VWF multimers (plasmin, neutro-
phil elastase) are recruited as discussed above. The local proteolytic
potential for VWF cleavage can be highly variable, because the activ-
ity of thrombin, plasmin, neutrophil elastase depends onmultifactori-
al activation or cellular release [25], but at the concentrations used in
the present study these proteases appear to be even more efﬁcient
than ADAMTS-13. According to an earlier report [44] the half-life of
VWF is more than 3 h when exposed in vitro to 6.7 nM ADAMTS-13
corresponding to its physiological plasma level [45], whereas our
data evidence more extensive VWF degradation within 30 min at en-
zyme concentrations of similar magnitude and physiological rele-
vance (Fig. 1). The direct effects of thrombin and plasmin on VWFmay compensate for the known inactivation of ADAMTS-13 by these
proteases [46].
Shear forces [5,16] and ristocetin [47] modify the conformation of
VWF so that it can bind the GpIb receptor of platelets with conse-
quent adhesion or agglutination. In our proteolytic assay under ﬂow
conditions (Fig. 3) the increased partial degradation of VWF by plas-
min, neutrophil elastase and thrombin suggests that shear-induced
conformational change promotes a more general proteolytic suscepti-
bility similar to that reported for ADAMTS-13 [8]. The presence of
platelets further sensitizes VWF to plasmin cleavage under ﬂow
(Fig. 3), thus contributing to the fragility of platelet-rich thrombi ex-
posed to high shear stress. According to this result suppression of
plasmin activity in the initial stages of hemostatic plug formation ap-
pears to be essential in a post-injury state. Thus, the hemorrhagic
trend in patients with plasminogen activator inhibitor-1 deﬁciency
can be attributed not only to the failure of the anti-ﬁbrinolytic de-
fense [48], but also to the compromised stability of platelet adhesion.
In view of the sensitizing effect of shear on VWF degradation by the
reported serine proteases, the ﬂow-borne large mass of plasma prote-
ase inhibitors acquires an essential supportive role in the propagation
phase of thrombus formation in vivo as a factor opposing the local
proteolysis and thus protecting the adhesive molecule.
In contrast to proteolysis under ﬂow, platelets block VWF degra-
dation partially (with plasmin, Fig. 2) or completely (with neutrophil
elastase and thrombin, not shown) under static conditions. Through
the maintenance of VWF integrity, this interplay of platelets, VWF
and plasmin appears to act as a synergetic mechanism in the recently
described VWF-dependent protection of ﬁbrinogen against plasmin
[23]. A concept for self-supporting interplatelet-cohesion circuit
emerges from these results: platelets moderate the digestion of
VWF, which in turn protects ﬁbrinogen against plasmin [23] and
ﬁnally both adhesive molecules contribute to the intercellular bridges
between platelets [49]. Thus, in compartments devoid of shear effects
(occlusive thrombi, vessels with slow blood ﬂow) the stability of
blood clots may be largely dependent on the proteolytic protective
effects of platelets on all three cohesive molecules (ﬁbrin, ﬁbrinogen
and VWF) in thrombi.
The present study evaluated the alternative proteolysis of VWF in
association with its functional consequences in shear-dependent
platelet adhesion. For the ﬁrst time we show that plasmin, neutrophil
elastase and thrombin can detach platelets anchored at high shear
stress in a VWF-dependent manner to collagen matrix or inner layers
of arteries (Fig. 4). Because under the conditions of our experiments
the platelet receptors (GpIb, GpIIb/IIIa) are known to be protected
against proteolysis with plasmin [31], this anti-adhesive effect of
the proteases can be attributed to the digestion of VWF, which is
clearly demonstrated with the immunoblots of perfusate from the
platelet-adhesion assay (Fig. 3). These results concerning platelet
adhesion are in agreement with earlier studies on the inhibition of
shear stress-induced platelet aggregation by plasmin, which has
been shown to be the consequence of degradation of VWF and not
of platelet receptors [50]. In our static experimental setup (Fig. 2)
only plasmin could reduce ristocetin-induced platelet agglutination
in parallel with VWF degradation (Fig. 2, Inset). Proteases (neutrophil
elastase, thrombin), which do not digest VWF in the presence of
platelets, could not suppress ristocetin-induced platelet agglutination
in our assay system. This result supports the abovementioned conclu-
sion that in the shear-dependent assay proteolysis of VWF (and not
platelet receptors) is responsible for the detachment of adhered
platelets when exposed to plasmin, neutrophil elastase or thrombin.
In conclusion, the present study conﬁrms the potential of
proteases with known occurrence in thrombi to modify the platelet
adhesive function of VWF under high shear stress and proves that
this effect depends on proteolysis exerted at physiologically relevant
enzyme concentrations. This alternative route for control of VWF
function is probably restricted to local compartments in blood clots,
e46 N. Wohner et al. / Thrombosis Research 129 (2012) e41–e46where these proteases are relatively protected against their abundant
plasma inhibitors.
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